AAN 2023 | NMOSDCopilot: smartphone-based digital biomarkers
NMOSDCopilot is a mobile app that tracks the progress of patients with neuromyelitis optica spectrum disorder (NMOSD). Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, explains the importance of this app in showing the level of neurological function at home on a more frequent basis. The current analysis of the progression of a patient’s disease and response to treatment is commonly made once or twice a year, but with this app, you can frequently sample a patient’s broader function, collecting data on the patient’s mobility, vision, cognition, and coordination. Dr. Levy hopes this will be used more in NMOSD to provide a broader idea of how people are managing in the long term. This interview took place at the AAN Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dr Levy receives consulting fees from Alexion, which is the manufacturer of ravulizumab, as well as other companies that make medications for NMOSD including Horizon (Amgen), and Genentech (Roche).
